BUCHANG PHARMA(SH:603858) Shang Hai Zheng Quan Bao·2025-11-25 18:55Group 1 - Company subsidiary Shanghai Hupu Medical Technology Co., Ltd. has recently obtained a new Medical Device Business License from the Shanghai Fengxian District Market Supervision Administration, involving changes in business scope, location, and warehouse address [1] - The change in the Medical Device Business License is based on actual operational needs and will not have a significant impact on the company's subsequent production and operations [1] Group 2 - On December 3, 2024, the company signed a Clinical Trial Entrustment Contract with Beijing Zhuoyue Future International Pharmaceutical Technology Development Co., Ltd. for the registration clinical trial of the product "Shenfu Yixin Granules" [4] - A supplementary agreement was signed, transferring all rights and obligations of the original contract to the company's wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., which will now handle the subsequent clinical research and registration procedures [5][6] - The signing of the supplementary agreement is expected to facilitate the smooth progress of the project, expand the company's business, enrich the product line, and strengthen market competitiveness without adversely affecting the company's financial status and operating results [7] Group 3 - The company announced adjustments to the members of its fifth board of directors' specialized committees due to the resignation of two directors, including one independent director, and the cancellation of the supervisory board [10] - The adjustments were made to improve the corporate governance structure and ensure the normal operation of the specialized committees [10] - The new members of the specialized committees will serve until the end of the current board's term and will continue to perform their respective duties until the next board's specialized committees are elected [11]